RIDDLE&CODE
19.1.2021 08:10:45 CET | Business Wire | Press release
RIDDLE&CODE, an innovative European provider of secure infrastructure and technology, and Securosys, a leader in cybersecurity, encryption and digital identity protection, today announced a strategic partnership. The partnership includes the provision of Securosys HSMs for RIDDLE&CODE's Token Management Platform (TPM).
The Token Management Platform is the next generation of RIDDLE&CODE's banking-grade digital asset management solution. Operating in a secure cloud infrastructure, it delivers scalable and flexible custodial and tokenization services to the financial, energy and metal industries in Europe. Regulatory compliance has been achieved in collaboration with the Swiss financial industry.
Securosys HSMs add banking grade security features and relevant compliance processes to RIDDLE&CODE’s TMP platform.
“Our Token Management Platform is now fully interoperable with Securosys HSMs, delivering an unmatched combination of versatility and security to our customers in the energy, finance, material and mobility sectors. We are delighted to partner with Securosys and appreciate its European industry recognition and expertise. The successful deployment and integration of our software with Securosys hardware in the Swiss financial industry made this partnership a natural choice for us.” Alexander Koppel, CEO of RIDDLE&CODE.
Securosys Primus HSMs are a robust solution for securing crypto assets. Its enterprise-grade security is continuously being enhanced with additional features to protect new blockchain systems entering the market. The main advantage of HSMs is a strong security guarantee through tamper resistance and strict access controls for administrative operations.
"We are pleased to deliver our Primus HSM for Riddle&Code's Token Management Platform," said Robert Rogenmoser, CEO of Securosys. "Securosys' Blockchain HSM not only provides the best protection for private keys, but also delivers integrated multisig authentication and algorithms for distributed ledger technologies."
Riddle&Code
RIDDLE&CODE is the leading European Blockchain interface company that builds hardware and software stacks and brings trusted identity to objects and people in the financial markets, energy distribution, mobility and the Internet of Things.
Securosys SA
Securosys SA, based in Zurich, Switzerland, is a market leader in cyber security, encryption, and in securing digital identities. Founded in 2014, Securosys secures the Swiss financial markets on behalf of the Swiss National Bank and protects transactions worth over 100 billion Euros every day. The company supplies more than half of the Tier 1 banks worldwide with hardware security modules developed and built in Switzerland.
Securosys offers a wide range of security network appliances focused on commercial applications. These include communication encryption and key generation and management. All products are developed and manufactured in Switzerland, free from contaminating influences.
Further information can be obtained directly from Securosys SA by e-mail at info@securosys.ch , by calling +41 44 552 31 00, or from its offices in Zürich, Munich, and Hong Kong.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005375/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom